核苷酸结合寡聚化结构域NOD样受体（NLRs）研究进展

生物技术通报 ›› 2013, Vol. 0 ›› Issue (7): 36-40.

核苷酸结合寡聚化结构域NOD样受体（NLRs）研究进展

李奕平,王潇

（内蒙古大学生命科学学院，呼和浩特 010021）

收稿日期:2013-03-18 修回日期:2013-07-19 出版日期:2013-07-19 发布日期:2013-09-02
作者简介:李奕平，女，研究方向：分子免疫学；E-mail：yipingli1991@sina.com
基金资助:
内蒙古自然科学基金项目（2010MS0514），内蒙古大学校级创新训练计划项目（2012156）

Advance in the Nucleotide Binding and Oligomerization Domain （NOD）-like Receptors （NLRs）

Li Yiping, Wang Xiao

（College of Life Sciences of Inner Mongolia University，Hohhot 010021）

Received:2013-03-18 Revised:2013-07-19 Published:2013-07-19 Online:2013-09-02

摘要/Abstract

摘要： 先天免疫系统是防御微生物的第一道防线。最近几年，人们发现一种新的蛋白家族——核苷酸结合寡聚化结构域NOD样受体(NLRs)，可以识别、抵御微生物病原体，在动物和植物体内的先天免疫中起重要作用。NLR蛋白激活后导致NF-κB，MAPK或半胱氨酸天冬氨酸酶的激活，从而介导炎症反应。对NLR家族及与之相关的炎症性疾病进行论述，并对NLR家族在炎症性疾病治疗的应用前景作展望。

关键词: 先天免疫, NLRs, NOD1, NOD2, 炎症疾病

Abstract: The innate immune system is the first line of defense against microorganisms, recent studies identified a new kind of protein, the nucleotide binding and oligomerization domain (NOD)-like receptors (NLRs) which can recognize and respond against pathogens, play an important role in the innate immune of the plant and animal. Activation of NLR proteins results in inflammatory responses mediated either by NF-κB, MAPK or Caspase-1 activation. The paper summarized the NLR family and the inflammatory diseases associated with it. The NLR family in the treatment of inflammatory diseases were also prospected.

Key words: Innate immune, NLRs, NOD1, NOD2, Inflammatory diseases

李奕平,王潇. 核苷酸结合寡聚化结构域NOD样受体（NLRs）研究进展[J]. 生物技术通报, 2013, 0(7): 36-40.

Li Yiping, Wang Xiao. Advance in the Nucleotide Binding and Oligomerization Domain （NOD）-like Receptors （NLRs）[J]. Biotechnology Bulletin, 2013, 0(7): 36-40.

参考文献

[1] Bergboer JG, Zeeuwen PL, Schalkwijk J. Genetics of psoriasis：evidence for epistatic interaction between skin barrier abnormalities andimmune deviation[J]. Invest Dermatol, 2012, 132（10）：2320-2321.
[2] Kanneganti TD, Lamkanfi M, Nú?ez G. Intracellular NOD-like receptors in host defense and disease[J]. Immunity, 2007, 27（4）：549-559.
[3] Akira S. Innate immunity and adjuvants[J]. Philos Trans R Soc Lond B Biol Sci, 2011, 366（1579）：2748-2755.
[4] Monie TP, Bryant CE, Gay NJ. Activating immunity：lessons from the TLRs and NLRs[J]. Trends Biochem Sci, 2009, 34（11）：5553-5561.
[5] Inohara N, Nunez G. Cell death and immunity：NODs：intracellular proteins involved in inflammation and apoptosis[J]. Nat Rev Immunol, 2003, 3：371-382.
[6] Ye ZM, Ting JPY. NLR, the nucleotide-binding domain leucine-rich repeat containing gene family[J]. Curr Opin Immunol, 2008, 20（1）：3-9.
[7] Wilmanski JM, Petnicki-Ocwieja T, Kobayashi KS. NLR proteins：integral members of innate immunity and mediators of inflammatory diseases[J]. Leukoc Biol, 2008, 83（1）：13-30.
[8] Proell M, Riedl SJ, Fritz JH, et al. The nod-like receptor（NLR）family：a tale of similarities and differences[J]. PLoS One, 2008, 3（4）：e2119.
[9] Bonardi V, Dangl JL. How complex are intracellular immune receptor signaling complexes?[J]. Frontiers in Plant Science, 2012, 3：237.
[10] Correa RG, Milutinovic S, Reed JC. Roles of NOD1（NLRC1）and NOD2（NLRC2）in innate immunity and inflammatory diseases[J]. Biosci Rep, 2012, 32：597-608.
[11] Kaparakis M, Philpott DJ, Ferrero RL. Mammalian NLR proteins；discriminating foe from friend[J]. Immunology and Cell Biology, 2007, 85：495-502.
[12] Magalhaes JG, Philpott DJ, Nahori MA, et al. Murine Nod1 but not its human orthologue mediates innate immune detection of tracheal cytotoxin[J]. EMBO Rep, 2005, 6：1201-1207.
[13] Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response[J]. Nature, 2006, 442：39-44.
[14] Tattoli I, Travassos LH, Carneiro LA, et al. The nodosome：Nod1 and Nod2 control bacterial infections and inflammation[J]. Semin Immunopathol, 2007, 29（3）：289-301.
[15] Correa RG, Milutinovic S, Reed JC. Roles of NOD1（NLRC1）and NOD2（NLRC2）in innate immunity and inflammatory diseases[J]. Biosci Rep, 2012, 32：597-608.
[16] Seth RB, Sun L, Chen ZJ. Antiviral innate immunity pathways[J]. Cell Res, 2006, 16：141-147.
[17] Watanabe T, Asano N, Fichtner-Feigl S, et al. NOD1 contributes to mouse host defense against Helicobacter pylori via induction of type I IFN and activation of the ISGF3 signaling pathway[J]. Clin Invest, 2010, 120：1645-1662.
[18] Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation[J]. Nat Med, 2010, 16：90-97.
[19] Travassos LH, Carneiro LA, Ramjeet M, et al. NOD1 and NOD2 direct autophagy by recruitingATG16L1 to the plasma membrane at the site of bacterial entry[J]. Nat Immunol, 2010, 11：55-62.
[20] Travassos LH, Carneiro LA, Girardin S, Philpott DJ. NOD proteins link bacterial sensing and autophagy[J]. Autophagy, 2010, 6：409-411.
[21] Uehara A, Fujimoto Y, Fukase K, Takada H. Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines[J]. Mol Immunol, 2007, 44（12）：3100-3111.
[22] Kim YG, Park JH, Daignault S, et al. Cross-tolerization between NOD1 and NOD2 signaling results in reduced refractoriness to bacterial infection in NOD2-deficient macrophages[J]. Immunol, 2008, 181：4340-4346.
[23] Rosenstiel P, Till A, Schreiber S. NOD-like receptors and human diseases[J]. Microbes and Infection, 2007,9（5）： 648-657.
[24] Schreiber S, Rosenstiel P, Albrecht M, et al. Genet-ics of Crohn disease, an archetypal inflammatory barrier disease[J]. Nat Rev Genet, 2005, 6：376-388.
[25] Biswas A, Petnicki-Ocwieja T, Kobayashi KS. Nod2：a key regulator linking microbiota to intestinal mucosal immunity[J]. Mol Med（Berl）, 2012, 90（1）：15-24.
[26] 黄鸿眉. NOD1、NOD2：两个重要的天然免疫胞内识别受体[J].国际免疫学杂志, 2006, 29（1）：23-26.
[27] Podolsky DK. Inflammatory bowel disease[J]N Engl J Med, 1991, 325：928-937.
[28] Bonen DK, Ogura Y, Nicolae DL, et al. Crohn’s disease-associated NOD2 variants share a signalling defect in response to lipopolysac-charide and peptidoglycan[J]. Gastroenterol, 2003, 124：140-146.
[29] Albrecht M, Domingues FS, Schreiber S, Lengauer T. Structural localization of disease-associated sequence variations in the NACHT and LRR domains of PYPAF1 and NOD2[J]. FEBS Lett, 2003, 554（3）：520-528.
[30] Borzutzky A, Fried A, Chou J, et al. NOD2-associated diseases：Bridging innate immunity and autoinflammation[J]. Clin Immunol, 2010, 134（3）：251-261.
[31] Okafuji I, Nishikomori R, Kanazawa N, et al. Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis[J]. Rthritis Rheum, 2009, 60（1）：242-250.